I can think of a couple but I imagine Protalix thinks that since the claims covering Enbel’s composition in patent #8,063,182 are specific to production of the protein in CHO cells (see for example claim #8), they might work around the AMGN patent by producing it in plant cell.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.